[1]. First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial.
Lung cancer (Amsterdam, Netherlands) [Volume]201 [Page]108109 (2025/) [Reviewed] Yes
[DOI] [2]. 皮膚科医に知ってほしい肺サルコイドーシス
皮膚科 [Volume]6 [Issue]4 [Page]389 -394 (2024/) [Reviewed] Yes
[3]. Risk factors for relapse of immune-related pneumonitis after 6-week oral prednisolone therapy: a follow-up analysis of a phase II study
BMC pulmonary medicine [Volume]24 [Issue]1 [Page]495 (2024/) [Reviewed] Yes
[4]. 臨床薬理の進歩 2024(45号)
(2024/) [Reviewed] Yes
[5]. Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [Page]JCO2400278 (2024/) [Reviewed] Yes
[Repository]